Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;113(4):460-464.
doi: 10.1111/ejh.14257. Epub 2024 Jun 18.

Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem-cell support for refractory/relapsed multiple myeloma

Carolina Perrone Marques  1 , Danielle Ovigli  1 , Mariana Nassif Kerbauy  1 , Ana Carolina de Almeida Silveira  1 , Ricardo Helman  1 , Cinthya Correa da Silva  1 , Andreza Alice Feitosa Ribeiro  1 , Nelson Hamerschlak  1 , Leonardo Javier Arcuri  1   2
Affiliations

Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem-cell support for refractory/relapsed multiple myeloma

Carolina Perrone Marques et al. Eur J Haematol. 2024 Oct.

Abstract

Introduction: Triple- and quad-refractory multiple myeloma patients usually have an aggressive course and a poor prognosis. Available therapeutic options are scarce.

Methods: The objective of the current study was to evaluate responses and toxicities of VDTPACE or mCBAD with hematopoietic stem-cell support as a bridge to subsequent therapies in patients with refractory/relapsed multiple myeloma.

Results: Thirteen patients were included (11 mCBAD, 2 VDTPACE), and 21 cycles of chemotherapy with hematopoietic stem-cell support were delivered. Mean number of previous therapies was 4.8. Stem cells were infused on a median day 9.9 after chemotherapy. Mean time to neutrophil recovery was 18.2 days in patients receiving the first cycle and 15.9 following subsequent cycles. Before therapy, most patients were in PD (77%), PR (15%), or VGPR (8%). Following treatment, the best responses achieved were PR (46%), VGPR (46%), and CR (8%). Median overall and progression-free survivals were 17 and 9 months. There has been no case of non-relapse mortality. In the 21 cycles, the main complications were infectious.

Conclusion: Intensive chemotherapy can decrease disease burden in patients with relapsed/refractory MM, and stem-cell support can successfully decrease toxicities and treatment-related mortality associated with these regimens and may be a good bridging option.

Keywords: bridging chemotherapy; hematopoietic stem‐cell support; intensive chemotherapy; relapsed/refractory multiple myeloma.

PubMed Disclaimer

References

REFERENCES

    1. Swerdlow SH, Campo E, Harris NL, et al. In: Weltgesundheitsorganisation, International Agency for Research on Cancer, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer; 2017:585 (World Health Organization classification of tumours).
    1. Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem‐cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2023 Feb;24(2):139‐150.
    1. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781‐794.
    1. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT‐2 study. Blood Cancer J. 2020 Sep 4;10(9):91.
    1. Richardson PG, Harrison SJ, Bringhen S, et al. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the phase III ICARIA‐MM study. Future Oncol. 2021 Dec;17(34):4797‐4812.

Grants and funding